Navigation Links
Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe
Date:11/19/2009

MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that the leading driver of antibiotic selection in nosocomial pneumonia in Europe is broad-spectrum activity against gram-positive and gram-negative pathogens. Due to the variety of organisms that can cause nosocomial pneumonia, surveyed European physicians reveal that they look primarily for agents that provide appropriate coverage against common pathogens, particularly for empiric therapy.

"Nosocomial pneumonia is an extremely important indication in Europe because it is a significant cause of morbidity and mortality," stated Decision Resources Analyst Lisa Arias. "Prescribing for nosocomial pneumonia is heavily driven by the need for timely, effective empiric therapy, and European specialists cite Pseudomonas and MRSA as the most concerning pathogens in nosocomial pneumonia."

In the new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia, surveyed European infectious disease specialists were highly receptive toward new antibiotics in late-stage development, including the two next-generation anti-MRSA cephalosporins (Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca's ceftaroline) and the novel anti-MRSA lipoglycopeptide telavancin (Astellas/Theravance/Takeda's Vibativ). European physicians indicate that these therapies could be used in empiric therapy for nosocomial pneumonia when the pathogen is unknown and MRSA infection is suspected. Because European specialists foresee an increase in the incidence of MRSA nosocomial pneumonia in the next five years, these therapies may become useful additions to the antibiotic armamentarium, offering much needed novel treatment options for MRSA nosocomial pneumonia.

"There are limited therapeutic options to target resistant pathogens in nosocomial pneumonia, so there is high unmet need for new, effective therapies in this indication. The broad-spectrum anti-MRSA cephalosporins may offer a convenient monotherapy option for European specialists who would like broad-spectrum nosocomial pneumonia agents possessing activity against troubling pathogens such as MRSA," continued Ms. Arias.

About the Report

AMR and Decision Resources' Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. This report contains European data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com

SOURCE Decision Resources; Arlington Medical Resources


'/>"/>
SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
6. Monetary gain and high-risk tactics stimulate activity in the brain
7. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
8. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
9. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" ... Liver Congress ("ILC") 2017 of the European Association for the ... on the positive effects of PBI-4050 on reduction of ... metabolic syndrome. ... Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and the ... sharing and commercialization model. , The Center for Advancing Innovation helps institutions maximize ... effort is bringing the IP to the attention of the entrepreneurial community and ...
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and CEO ... from the Purdue College of Pharmacy in Lafayette, Indiana. , The Distinguished Alumni ... achievements in their careers and other scientific endeavors. , Wright began her career ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):